BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI (TEM) to $105 from $96 and keeps a Buy rating on the shares after meeting with its management team. Tempus AI outlined several durable growth drivers, namely that its data/pharma business is robust and diversified, Ambry’s growth has tracked ahead of its deal model and is expected to grow over 20%, with rare disease testing as a complementary growth driver, and that its algo business might be a sleeper and could deliver over 80% gross margins with time, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Cathie Wood Sells Tesla (TSLA) and SoFi Stocks, Makes a $34M Bet on This USDC Giant
- Tempus AI management to meet virtually with BTIG
- Tempus AI price target raised to $80 from $68 at Morgan Stanley
- Tempus AI price target lowered to $80 from $105 at Piper Sandler
- Tempus AI price target lowered to $89 from $98 at H.C. Wainwright